Felix Geissler
No más puestos en curso
Perfil
Felix Geissler served as Vice President-Medical Affairs at Curis, Inc. in 2022-2023.
Prior to that, he held the same position at Horizon Therapeutics Plc.
He also served as Chief Medical Officer at Lumicell, Inc. and as SVP, Head-Oncology, Hematology & Transplant at Sanofi Corp.
Geissler holds a doctorate degree from the University of Innsbruck, Eberhard Karls Universität Tübingen, and Ludwig-Maximilians-Universität München.
Antiguos cargos conocidos de Felix Geissler.
Empresas | Cargo | Fin |
---|---|---|
CURIS, INC. | Director Técnico/Científico/I+D | 01/01/2023 |
Sanofi Corp. | Corporate Officer/Principal | - |
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Lumicell, Inc. develops and markets image-guided cancer surgery solutions. It offers Lumicell System, designed to enable surgeons to see residual cancer cells in the cavity walls in real-time during surgery. The company was founded by Linda G. Griffith, David G. Kirsch, Jorge M. Ferrer, Ralph Weissleder, W. David Lee, Andrey J. Zarur, and Moungi G. Bawendi in 2008 and is headquartered in Wellesley, MA. | Director Técnico/Científico/I+D | - |
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Director Técnico/Científico/I+D | - |
Formación de Felix Geissler.
Eberhard Karls Universität Tübingen | Doctorate Degree |
University of Innsbruck | Doctorate Degree |
Ludwig-Maximilians-Universität München | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
CURIS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Lumicell, Inc. develops and markets image-guided cancer surgery solutions. It offers Lumicell System, designed to enable surgeons to see residual cancer cells in the cavity walls in real-time during surgery. The company was founded by Linda G. Griffith, David G. Kirsch, Jorge M. Ferrer, Ralph Weissleder, W. David Lee, Andrey J. Zarur, and Moungi G. Bawendi in 2008 and is headquartered in Wellesley, MA. | Electronic Technology |
Sanofi Corp. |
- Bolsa de valores
- Insiders
- Felix Geissler